Xingwei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xingwei Zhang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Chuan‐Bin Shen
School of Clinical Medicine Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University Hangzhou China
1 shared publication - Guofan Chen1 shared publication
- Hangzhou Luo1 shared publication
- Huaiming Peng1 shared publication
- Hui Luo
School of Clinical Medicine, Hangzhou Normal University, Hangzhou 311121, China
1 shared publication - Jiang Liu
Zhejiang Key Laboratory of Medical Epigenetics, Department of Cell Biology and Genetics, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou, Zhejiang, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2025 (1)
Immediate Effect of Drug‐Eluting Balloon Angioplasty Combined With Cutting Balloon Predilatation for the Treatment of Coronary Artery Disease
Background: Cutting balloon (CB) can reduce vascular inflammation and elastic recoil, and these findings have been verified in combination with stent implantation in patients with coronary artery disease (CAD). This study aims to compare the immediate effect of CB with conventional balloon pre‐dilatation before drug‐eluting balloon (DEB) angioplasty for the treatment of CAD. Methods: Patients with CAD, diagnosed by elective coronary angiography and having either de novo lesions or in‐stent restenosis (ISR) were included. All patients were randomly assigned to undergo predilatation with either a CB or a conventional balloon prior to DEB treatment. We assessed the immediate effect and the level of inflammatory factors after the operation between two groups. Results: Eighty‐five patients were enrolled. In the CB group ( n = 42), all patients achieved residual stenosis < 30% (100% procedural success), with no acute complications observed. In the conventional balloon group ( n = 43), 6 patients had residual stenosis ≥ 30% (resulting in an 86.0% procedural success rate), and two acute complications occurred (one type B dissection and one acute branch occlusion), neither requiring bail‐out stenting. Moreover, serum levels of IL‐6, IL‐8, TNF‐α, and CRP at 24 h were significantly higher than those before and immediately after the operation in the two groups. The degrees of increase in concentration of IL‐6, IL‐8, and TNF‐α 24‐h postoperatively were lower in the CB group than those in the conventional balloon group ( P < 0.05). Conclusions: In the treatment of CAD with DEB angioplasty, predilatation with CB was associated with improved immediate procedural success and a reduced inflammatory response compared with conventional balloon predilatation.
- 1 January 2025
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2025 (1)
Open AccessImmediate Effect of Drug‐Eluting Balloon Angioplasty Combined With Cutting Balloon Predilatation for the Treatment of Coronary Artery Disease
Background: Cutting balloon (CB) can reduce vascular inflammation and elastic recoil, and these findings have been verified in combination with stent implantation in patients with coronary artery disease (CAD). This study aims to compare the immediate effect of CB with conventional balloon pre‐dilatation before drug‐eluting balloon (DEB) angioplasty for the treatment of CAD. Methods: Patients with CAD, diagnosed by elective coronary angiography and having either de novo lesions or in‐stent restenosis (ISR) were included. All patients were randomly assigned to undergo predilatation with either a CB or a conventional balloon prior to DEB treatment. We assessed the immediate effect and the level of inflammatory factors after the operation between two groups. Results: Eighty‐five patients were enrolled. In the CB group ( n = 42), all patients achieved residual stenosis < 30% (100% procedural success), with no acute complications observed. In the conventional balloon group ( n = 43), 6 patients had residual stenosis ≥ 30% (resulting in an 86.0% procedural success rate), and two acute complications occurred (one type B dissection and one acute branch occlusion), neither requiring bail‐out stenting. Moreover, serum levels of IL‐6, IL‐8, TNF‐α, and CRP at 24 h were significantly higher than those before and immediately after the operation in the two groups. The degrees of increase in concentration of IL‐6, IL‐8, and TNF‐α 24‐h postoperatively were lower in the CB group than those in the conventional balloon group ( P < 0.05). Conclusions: In the treatment of CAD with DEB angioplasty, predilatation with CB was associated with improved immediate procedural success and a reduced inflammatory response compared with conventional balloon predilatation.
- 5 October 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (11) , e23221
UFMylation of HRD1 regulates endoplasmic reticulum homeostasis
Ubiquitin fold modifier 1 is a small ubiquitin‐like protein modifier that is essential for embryonic development of metazoans. Although UFMylation has been connected to endoplasmic reticulum homeostasis, the underlying mechanisms and the relevant cellular targets are largely unknown. Here, we show that HRD1, a ubiquitin ligase of ER‐associated protein degradation (ERAD), is a novel substrate of UFM1 conjugation. HRD1 interacts with UFMylation components UFL1 and DDRGK1 and is UFMylated at Lys610 residue. In UFL1‐depleted cells, the stability of HRD1 is increased and its ubiquitination modification is reduced. In the event of ER stress, the UFMylation and ubiquitination modification of HRD1 is gradually inhibited over time. Alteration of HRD1 Lys610 residue to arginine impairs its ability to degrade unfolded or misfolded proteins to disturb protein processing in ER. These results suggest that UFMylation of HRD1 facilitates ERAD function to maintain ER homeostasis.
- 5 October 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (11) , e23221
UFMylation of HRD1 regulates endoplasmic reticulum homeostasis
Ubiquitin fold modifier 1 is a small ubiquitin‐like protein modifier that is essential for embryonic development of metazoans. Although UFMylation has been connected to endoplasmic reticulum homeostasis, the underlying mechanisms and the relevant cellular targets are largely unknown. Here, we show that HRD1, a ubiquitin ligase of ER‐associated protein degradation (ERAD), is a novel substrate of UFM1 conjugation. HRD1 interacts with UFMylation components UFL1 and DDRGK1 and is UFMylated at Lys610 residue. In UFL1‐depleted cells, the stability of HRD1 is increased and its ubiquitination modification is reduced. In the event of ER stress, the UFMylation and ubiquitination modification of HRD1 is gradually inhibited over time. Alteration of HRD1 Lys610 residue to arginine impairs its ability to degrade unfolded or misfolded proteins to disturb protein processing in ER. These results suggest that UFMylation of HRD1 facilitates ERAD function to maintain ER homeostasis.